Walking the dog and moving the cat: Rabies serology in the context of international pet travel schemes

Schweizer Archiv fur Tierheilkunde

Volumn 152, Issue 12, 2010, Pages 561-568

  Zanoni, R G ^a   Bugnon, Ph ^b   Deranleau, E ^a   Nguyen, T M V ^a   Brugger D ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Breed; Pet travel schemes; Rabies; Regimen; Serology; Vaccine

Indexed keywords

RABIES VACCINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; DISEASE TRANSMISSION; DOG; DOG DISEASE; IMMUNIZATION; RABIES; STATISTICS; TRAVEL; VIROLOGY;

ANIMALS; CAT DISEASES; CATS; DISEASE TRANSMISSION, INFECTIOUS; DOG DISEASES; DOGS; IMMUNIZATION, SECONDARY; RABIES; RABIES VACCINES; TRAVEL;

CANIS FAMILIARIS;

EID: 78649892105     PISSN: 00367281     EISSN: None     Source Type: Journal    
DOI: 10.1024/0036-7281/a000125     Document Type: Article

References (51)

1. Anonymous: Rabies vaccination for Norway and Sweden - a second follow-up vaccination provides more safety. Tijdschr. Diergeneeskd. 1996, 121: 44.
2. Anonymous: Rabies vaccine (inactivated) for veterinary use. In: European Pharmacopoeia 5.0, 5th ed., Council of Europe, Strasbourg, 2005, 790-792.
3. Anonymous: User's Guide, NCSS Statistical System. Ed. Dr. Jerry L. Hintze, NCSS, Kaysville, Utah 84037, 2007.
4. Barth R., Franke V., Müller H., Weinmann E.: Purifi ed chickembryo-cell (PCEC) rabies vaccine - its potency performance in different test systems and in humans. Vaccine 1990, 8: 41-48.
5. Bernasconi N.L., Traggiai E., Lanzavecchia A.: Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298: 2199-2202.
6. Blancou J., Baltazar R.S., Molli I., Stoltz J.F.: Effective postexposure treatment of rabies-infected sheep with rabies immune globulin and vaccine. Vaccine 1991, 9: 432-437.
7. Bundesamt für Veterinärwesen: Einfuhrbedingungen für Hunde und Katzen. Mitteilungen BVET 2003a, 14/2005: 283-288.
8. Bundesamt für Veterinärwesen: Neue Einfuhrbedingungen für Hunde und Katzen. Mitteilungen BVET 2003b, 13/2003: 200-201.
9. Bunn T.O.: Canine and feline vaccines, past and present. In: The natural history of rabies, Ed. G. M. Baer, CRC Press, Boca Raton, Ann Arbor, Boston, 1991, 415-425.
10. Bunschoten H., Klapmuts R.J., Claassen I.J.T.M., Reyneveld S.D., Osterhaus A.D.M.E., Uytdehaag F.G.C.M.: Rabies virus-specifi c human T cell clones provide help for an in vitro antibody response against neutralizing antibody-inducing determinants of the viral glycoprotein. J.Gen.Virol. 1989, 70: 1513-1521.
11. Cho H.C., Lawson K.F.: Protection of dogs against death from experimental rabies by postexposure administration of rabies vaccine and hyperimmune globulin (human). Can.J.Vet.Res.-Rev.Can.Rech.Vet. 1989, 53: 434-437.
12. Clark K.A., Wilson P.J.: Postexposure rabies prophylaxis and preexposure rabies vaccination failure in domestic animals. J.Am.Vet.Med.Assoc. 1996, 208: 1827-1830.
13. Cliquet F., Aubert M., Sagne L.: Development of a fl uorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J.Immunol.Methods 1998, 212: 79-87.
14. Cliquet F., Barrat J., Picard E.: "Au-delá des chiffres⋯Importation d'un cas de rage canine du Maroc en Gironde en août 2004: conséquences sur les activités de l'AFSSA Nancy". Bulletin Epidemiologique Mensuel de la Rage Animale en France 2005, 35/7 - 8 - 9: 1-5.
15. Cliquet F., Verdier Y., Sagne L., Aubert M., Schereffer J.L., Selve M., Wasniewski M., Servat A.: Neutralising antibody titration in 25,000 sera of dogs and cats vaccinated against rabies in France, in the framework of the new regulations that offer an alternative to quarantine. Rev.sci.tech.Off.int.Epiz. 2003, 22: 857-866.
16. Dacheux L., Bourhy H.: Identification de deux cas de rage chez des chiens introduits illégalement en France á partir de zones d'enzootie rabique. Bulletin Epidemiologique Mensuel de la Rage Animale en France 2008, 38/1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9: 1-5.
17. De Benedictis P., Mutinelli F., Veggiato C., Capua I., Squecco G., Coassin R., Ferri G.: Rabies in a vaccinated dog in Italy. Vet.Rec. 2009, 165: 216.
18. Dietzschold B., Gore M., Marchadier D., Niu H.-S., Bunschoten H.M., Otvos L., Jr., Wunner W.H., Ertl H.C.J., Osterhaus A.D.M.E., Koprowski H.: Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J.Virol. 1990, 64: 3804-3809.
19. Dietzschold B., Wang H., Rupprecht C.E., Celis E., Tollis M., Ertl H., Heber-Katz E., Koprowski H.: Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc.Natl.Acad.Sci.U.S.A. 1987, 84: 9165-9169.
20. Eurosurveillance: Identifi cation of a rabid dog illegally introduced from the Republic of the Gambia to Belgium and France. Euro.Surveill. 2008, 13: 1-2.
21. Fishbein D.B., Pacer R.E., Holmes D.F., Ley A.B., Yager P., Tong T.C.: Rabies preexposure prophylaxis with human diploid cell rabies vaccine: a dose-response study. J.Infect.Dis. 1987, 156: 50-55.
22. Fooks A.R., McElhinney L.M., Brookes S.M., Johnson N., Keene V., Parsons G., Soldan A.: Rabies antibody testing and the UK Pet Travel Scheme. Vet.Rec. 2002, 150: 428-430.
23. Herzog M., Lafage M., Montano-Hirose J.A., Fritzell C., Scott-Algara D., Lafon M.: Nucleocapsid specifi c T-cell and B-cell responses in humans after rabies vaccination. Virus Res. 1992, 24: 77-89.
24. Kaerber G.: Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch.exp.Pathol.Pharmakol. 1931, 162: 480-487.
25. Kawano H., Mifune K., Ohuchi M., Mannen K., Cho S., Hiramatsu K., Shichijo A.: Protection against rabies in mice by a cytotoxic T-cell clone recognizing the glycoprotein of rabies virus. J.Gen.Virol. 1990, 71: 281-287.
26. Kennedy L.J., Lunt M., Barnes A., McElhinney L., Fooks A.R., Baxter D.N., Ollier W.E.R.: Factors infl uencing the antibody response of dogs vaccinated against rabies. Vaccine 2007, 25: 8500-8507.
27. Klingeborn B., Krogsrud J.: Vaccination and antibody testing replacing quarantine as rabies safety measure for transfer of dogs and cats into Sweden and Norway from EU/EFTA-countries. Rabies Bulletin Europe 1993, 17/4: 13-14.
28. Lyng J.: Calibration of a replacement preparation for the international standard for rabies immunoglobulin. Biologicals 1994, 22: 249-255.
29. Mansfield K.L., Burr P.D., Snodgrass D.R., Sayers R., Fooks A.R.: Factors affecting the serological response of dogs and cats to rabies vaccination. Vet.Rec. 2004, 154: 423-426.
30. Mitmoonpitak C., Limusanno S., Khawplod P., Tepsumethanon V., Wilde H.: Post-exposure rabies treatment in pigs. Vaccine 2002, 20: 2019-2021.
31. Moore S.M., Ricke T.A., Davis R.D., Briggs D.J.: The infl uence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays. Biologicals 2005, 33: 269-276.
32. Murray K.O., Holmes K.C., Hanlon C.A.: Rabies in vaccinated dogs and cats in the United States, 1997 - 2001. J.Am.Vet.Med. Assoc. 2009, 235: 691-695.
33. Okoh A.E.J.: Antigenic characterization of rabies virus isolates from vaccinated dogs in Plateau State, Nigeria. Vet.Res.Commun. 2000, 24: 203-211.
34. Schwendenwein I., Gerstl F.: Atypical course of rabies in a vaccinated dog. Wien.Tierarztl.Monatsschr. 1993, 80: 108-112.
35. Sihvonen L., Kulonen K., Neuvonen E., Pekkanen K.: Rabies antibodies in vaccinated dogs. Acta Vet.Scand. 1995, 36: 87-91.
36. Smith J.S., Yager P.A., Baer G.M.: A rapid reproducible test for determining rabies neutralizing antibody. Bull.World Health Organ. 1973, 48: 535-541.
37. Spearman C.: The method of «right or wrong cases» (constant stimuli) without Gauss's formulae. Brit.J.Psychol. 1908, 2: 227-242.
38. Strady A., Lang J., Lienard M., Blondeau C., Jaussaud R., Plotkin S.A.: Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J.Infect.Dis. 1998, 177: 1290-1295.
39. Strady C., Nguyen V.H., Jaussaud R., Lang J., Lienard M., Strady A.: Pre-exposure rabies vaccination: strategies and cost-minimization study. Vaccine 2001, 19: 1416-1424.
40. Takahashi-Omoe H., Omoe K., Okabe N.: Regulatory systems for prevention and control of rabies, Japan. Emerg.Infect.Dis. 2008, 14: 1368-1374.
41. Tepsumethanon W., Polsuwan C., Lumlertdaecha B., Khawplod P., Hemachudha T., Chutivongse S., Wilde H., Chiewbamrungkiat M., Phanuphak P.: Immune response to rabies vaccine in Thai dogs - a preliminary report. Vaccine 1991, 9: 627-630.
42. French multidisciplinary investigation team: Identifi cation of a rabid dog in France illegally introduced from Morocco. Euro. Surveill. 2008, 13: 107-108.
43. Traggiai E., Puzone R., Lanzavecchia A.: Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine 2003, 21 Suppl 2: S35-S37.
44. Van Gucht S., Le Roux I.: Rabies control in Belgium: from eradication in foxes to import of a contaminated dog. Vlaams Diergen. Tijds. 2008, 77: 376-384.
45. Weber A., Keller B., Berg H., Schmahl W., Suss J., Muller T.: Case report: Rabies in a vaccinated dog imported from Azerbaijan. Prakt.Tierarzt 2003, 84: 912-914.
46. WHO: WHO expert consultation on rabies, fi rst report. In: WHO Technical Report Series 931, WHO, Geneva, 2005.
47. WHO: Rabies vaccine - update. Wkly.Epidemiol.Rec. 2007, 82: 62-68.
48. Wunderli P.S., Shaddock J.H., Schmid D.S., Miller T.J., Baer G.M.: The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines. Vaccine 1991, 9: 638-642.
49. Xiang Z.Q., Knowles B.B., McCarrick J.W., Ertl H.C.J.: Immune effector mechanisms required for protection to rabies virus. Virology 1995, 214: 398-404.
50. Zalan E., Wilson C., Pukitis D.: A microtest for the quantitation of rabies virus neutralizing antibodies. J.Biol.Stand. 1979, 7: 213-220.
51. Zanoni R., Breitenmoser U.: Rabies in a puppy in Nyon, Switzerland. Euro.Surveill. 2003, 7: 2-4.